WaveMan
WaveMan · Company
ZEOX · Zeo Scientifix, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

ZEOX Zeo ScientifiX (ZEOX) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Biological products, (no diagnostic substances) · CIK 0001557376
Quote by TradingView
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
0
13F, latest reported quarter

Zeo ScientifiX insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

No insider purchases or sales are on record for Zeo ScientifiX, Inc. in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
Skycrest Holdings, LLC
BUY
2025-06-27 SECtraded 2025-06-25
6,000
$12.0K
-22.8%
Context
  • 40 earlier Form 4 trades (code P or S) here by this insider (40 buys), the last on Jun 20, 2025.
  • -19.5% median (-21.2% mean) 90-day return after 30 previous buys.
  • The trade is 1.4% of the 416,371 shares held after it.
  • No other insider bought within 30 days.
Insider activity: Insider Skycrest Holdings, LLC bought about $12.0K of ZEOX on Jun 25, 2025.
Skycrest Holdings, LLC
BUY
2025-06-24 SECtraded 2025-06-20
1,002
$2.3K
-28.7%
Context
  • 39 earlier Form 4 trades (code P or S) here by this insider (39 buys), the last on Jun 18, 2025.
  • -18.2% median (-17.8% mean) 90-day return after 30 previous buys.
  • The trade is 0.2% of the 410,371 shares held after it.
  • No other insider bought within 30 days.
Insider activity: Insider Skycrest Holdings, LLC bought about $2.3K of ZEOX on Jun 20, 2025.
Skycrest Holdings, LLC
BUY
2025-06-24 SECtraded 2025-06-18
3,000
$6.1K
-28.7%
Context
  • 38 earlier Form 4 trades (code P or S) here by this insider (38 buys), the last on Jun 11, 2025.
  • -16.7% median (-14.8% mean) 90-day return after 30 previous buys.
  • The trade is 0.7% of the 409,369 shares held after it.
  • No other insider bought within 30 days.
Insider activity: Insider Skycrest Holdings, LLC bought about $6.1K of ZEOX on Jun 18, 2025.
Skycrest Holdings, LLC
BUY
2025-06-13 SECtraded 2025-06-11
524
$1.0K
-32.4%
Context
  • 37 earlier Form 4 trades (code P or S) here by this insider (37 buys), the last on Jun 9, 2025.
  • -15.2% median (-14.5% mean) 90-day return after 29 previous buys.
  • The trade is 0.1% of the 406,369 shares held after it.
  • No other insider bought within 30 days.
Insider activity: Insider Skycrest Holdings, LLC bought about $1.0K of ZEOX on Jun 11, 2025.
Skycrest Holdings, LLC
BUY
2025-06-12 SECtraded 2025-06-09
138
$275
-32.2%
Context
  • 36 earlier Form 4 trades (code P or S) here by this insider (36 buys), the last on Jun 6, 2025.
  • -15.2% median (-14.0% mean) 90-day return after 28 previous buys.
  • The trade is 0.0% of the 405,845 shares held after it.
  • No other insider bought within 30 days.
Insider activity: Insider Skycrest Holdings, LLC bought about $275 of ZEOX on Jun 9, 2025.
41 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 36 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
under five funds report holding it
Revenue
+12.5% year over year
more than 62% of Pharma & Biotech
Margin
-106.2% net margin
below 58% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
<0.1% of the float short (float per yahoo 2026-10-27) · 1.0 days to cover · settled 2026-10-15
the lowest in Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch ZEOX

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-28.7%12M
-55%-21%+14%+48%2025-102025-122026-022026-042026-062026-082026-10
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns ZEOX: institutional holders (13F)

13F holdings, latest reported quarter
SEC 13F
No reported 13F holders

No fund above the reporting threshold listed this stock last quarter. That is a fact, not missing data.

Congress trades in ZEOX

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

ZEOX planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
Clinical pipeline
4 registered trials, 0 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
1
Not applicable
0 active
3
Multi-phase
0 active
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
Each figure here is a federal filing, dated the day it went public, so you can test what was knowable then.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

ZEOX financials

Revenue growth
+12.5%
XBRL, annual
Net margin
-106.2%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$7.0M
four quarters, 2025-05-01 to 2026-04-30
Net margin, TTM
-55.6%
net income over revenue, 2025-05-01 to 2026-04-30
Free cash flow, TTM
n/a
capex not filed for the four quarters
Debt to equity
0.07x
LongTermDebt as filed 2024-07-31 (21 months older than the period end) (includes the current portion); equity 2026-04-30
Cash flow to debt
-24.49x
TTM operating cash flow over LongTermDebt as filed 2024-07-31 (21 months older than the period end) (includes the current portion)
Return on equity
n/a
average equity is zero or negative
Return on assets
-146.0%
TTM net income over average of 2025-04-30 and 2026-04-30
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on capital employed
n/a
capital employed is zero or negative
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
$9.5M
market value at close 2026-10-27 on 2026-10-12 shares, plus LongTermDebt as filed 2024-07-31 (21 months older than the period end) (includes the current portion), minus cash 2023-01-31
FCF yield
n/a
capex not filed for the four quarters
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-27. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-102024-102023-102022-10
Revenue$5.2M$4.6M$4.6M$6.5M
Gross profit$4.3M$3.8M$4.0M$5.7M
Operating income-$5.4M-$5.3M-$6.8M-$8.8M
Net income-$5.5M-$4.7M-$7.0M-$8.9M
EPS (diluted)-0.86-0.74-0.99-1.56
Operating cash flow-$718.0K-$1.4M-$2.2M-$3.2M
Cashn/an/an/a$3.8M
Long-term debtn/an/a$68.0Kn/a
SEC XBRL, fiscal years, as known on 2026-10-28

ZEOX Stock Sonar score 3/7 axes

Find similar shapesCompare

ZEOX ranks highest on risk and compliance (94th percentile) and growth (62nd), and lowest on financial health (38th), among Pharma & Biotech peers.

Financial health
38
Inputs
  • Debt to equity0.07x · 58 pct, sector of 352
  • Cash flow to debt-24.49x · 18 pct, sector of 371
Growth
62
Inputs
  • Revenue growth, YoY+12.5% · 62 pct, sector of 505
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Risk and compliance
94
Inputs
  • Short interest, % of float+0.0% · 97 pct, sector of 816
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-K+3.5% · 90 pct, sector of 511
4 not measured: Profitability, Insider conviction, Institutional and government, US patents
  • Profitability needs 2 of 4 inputs, 1 present: average equity is zero or negative; capital employed is zero or negative; tax provision or pre-tax income not filed for the four quarters
  • Insider conviction needs 1 of 2 inputs, 0 present: no Form 4 purchase or sale (code P or S) in 180 days; no insider trades in 180 days
  • Institutional and government needs 1 of 4 inputs, 0 present: fewer than five funds report holding it; no Congress trades in 365 days; no federal contracts in 180 days; no lobbying filings in the last four quarters
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

3 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies